Forschungsgruppe Morrison



  • Activation of Ras requires the ERM-dependent link of actin to the plasma membrane.
    Sperka T, Geissler KJ, Merkel U, Scholl I, Rubio I, Herrlich P, Morrison HL
    PLoS One 2011, 6(11), e27511
  • p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011)
    Stefan F, Solveigh C K, Stefan A L
    Expert Opin Ther Pat 2011, 21(12), 1843-66


  • Regulation of cellular actin architecture by S100A10.
    Jung* MJ, Murzik* U, Wehder L, Hemmerich P, Melle C
    Exp Cell Res 2010, 316(7), 1234-40 * equal contribution
  • What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.
    Kissil JL, Blakeley JO, Ferner RE, Huson SM, Kalamarides M, Mautner VF, McCormick F, Morrison H, Packer R, Ramesh V, Ratner N, Rauen KA, Stevenson DA, Hunter-Schaedle K, North K
    Am J Med Genet A 2010, 152A(2), 269-83
  • Merlin inhibits neurite outgrowth in the CNS.
    Schulz A, Geissler KJ, Kumar S, Leichsenring G, Morrison* H, Baader* SL
    J Neurosci 2010, 30(30), 10177-86 * equal contribution


  • Properties of an ezrin mutant defective in F-actin binding.
    Saleh HS, Merkel U, Geissler KJ, Sperka T, Sechi A, Breithaupt C, Morrison H
    J Mol Biol 2009, 385(4), 1015-31


  • Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac.
    Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P
    Cancer Res 2007, 67(2), 520-7
  • Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin.
    Orian-Rousseau* V, Morrison* H, Matzke A, Kastilan T, Pace G, Herrlich P, Ponta H
    Mol Biol Cell 2007, 18(1), 76-83 * equal contribution, published during change of institution